Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats

Journal of the American College of Cardiology

Volumn 28, Issue 6, 1996, Pages 1580-1588

  Sakai, Satoshi ^a   Miyauchi, Takashi ^a,b   Sakurai, Takeshi ^b   Yamaguchi, Iwao ^a   Kobayashi, Masahiko ^c   Goto, Katsutoshi ^b   Sugishita, Yasuro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

ANIMALS; ENDOTHELIN-1; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; KIDNEY; LUNG; PEPTIDES, CYCLIC; PROTEIN PRECURSORS; RATS; RECEPTORS, ENDOTHELIN; RNA, MESSENGER;

EID: 0030589015     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00336-1     Document Type: Article

References (44)

1. 1. Smith TW. Heart failure. In: Wyngaarden JB, Smith LH, Bennett JC, editors. Cecil Textbook of Medicine. Philadelphia: Saunders, 1992:187-207.
2. 2. Fishman AP. Pulmonary hypertension. In: Wyngaarden JB, Smith LH, Bennett JC, editors. Cecil Textbook of Medicine. Philadelphia: Saunders, 1992:269-80.
3. 3. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
4. 4. Miyauchi T, Tomobe Y, Shiba R, et al. Involvement of endothelin in the regulation of human vascular tonus. Potent vasoconstrictor effect and existence in endothelial cells. Circulation 1990;81:1874-80.
5. 5. Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation: implication for vascular function. Circulation 1991;84:1457-68.
6. 6. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathology. Pharmacol Rev 1994;45:325-415.
7. 7. Ryan US, Glassberg MK, Nolop KB. Endothelin-1 from pulmonary artery and microvessels acts on vascular and airway smooth muscle. J Cardiovasc Pharmacol 1989;13:S57-62.
8. 8. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993;73:887-97.
9. 9. Lippton HL, Hauth TA, Summer WR, Hyman AL. Endothelin produces pulmonary vasoconstriction and systemic vasodilation. J Appl Physiol 1989; 66:1008-12.
10. 10. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S. Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol 1990;258:C408-15.
11. 11. Takuwa N, Takuwa Y, Yanagisawa M, Yamashita K, Masaki T. A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J Biol Chem 1989;264:7856-61.
12. 12. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelly R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
13. 13. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992;85:510-7.
14. 14. Cacoub P, Dornet R, Nataf P, et al. Plasma endothelin and pulmonary pressures in patients with congestive heart failure. Am Heart J 1993;126: 1484-8.
15. 15. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin-1 in experimental heart failure. Circulation 1990;82: 2226-30.
16. 16. Sakai S, Miyauchi T, Sakurai T, et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 1996;93:1214-22.
17. 17. Shiba R, Yanagisawa M, Miyauchi T, et al. Elimination of intravenously injected endothelin-1 from circulation of the rat. J Cardiovasc Pharmacol 1989;13:S98-101.
18. 18. Ihara M, Noguchi K, Saeki T, et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992;50:247-55.
19. 19. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-12.
20. 20. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-12.
21. 21. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J 1991;121:1852-3.
22. 22. Miyauchi T, Yanagisawa M, Tomizawa T, et al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989;164:53-4.
23. 23. Sakurai T, Yanagisawa M, Inoue A, et al. cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun 1991;175:44-7.
24. 24. Kobayashi M, Nishikibe M, Maruyama H, et al. Localization and alteration of immunoreactive endothelin-1 in canine basilar arteries following subarachnoid hemorrhage. Acta Histochem Cytochem 1995;28:129-36.
25. 25. Davenport AP, Maguire JJ. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci 1994;15:9-11.
26. 26. Watanabe TX, Itahara Y, Nakajima K, Kumagaye S, Kimura T, Sakakibara S. The biological activity of endothelin-1 analogues in three different assay systems. J Cardiovasc Pharmacol 1991;17:S5-9.
27. 27. Fukuroda T, Kobayashi M, Ozaki S, et al. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol 1994;76:1976-82.
28. 28. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994;23:1423-33.
29. 29. Eaton GM, Bush CA, VanFossen DB, Kelley RE, Cody RJ. Absence of pulmonary endothelin gradient in patients with normal or elevated circulating endothelin. Am J Cardiol 1994;73:1015-6.
30. 2+ and protein kinase C in shear stress-induced actin depolymerization and endothelin-1 gene expression. Circ Res 1994;75:630-6.
31. 31. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Pressure enhances endothelin-1 release from cultured human endothelial cells. Hypertension 1995;25:449-52.
32. 32. Ishikawa S, Miyauchi T, Sakai S, et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg 1995;110:271-3.
33. 33. Li H, Chen SJ, Chen YF, et al. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol 1994;77:1451-9.
34. 34. Sakai S, Miyauchi T, Yamaguchi I, Sugishita Y, Goto K, Kobayashi M. Study of endothelin-1-like irnmunoreactivity in the lung of rats with pulmonary hypertension caused by monocrotaline [abstract]. Jpn Circ J 1995;59:507.
35. 35. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328: 1732-9.
36. 36. Nishikibe M, Tsuchida S, Okada M, et al. Antihypertensive effects of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci 1993;52:717-24.
37. 37. Teerlink JR, Loffler BM, Hess P, Maire JP, Clozel M, Clozel JP. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (Bosentan). Circulation 1994;90:2510-8.
38. 38. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
39. 39. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res 1991;69:370-7.
40. 40. Watanabe T, Awane Y, Ikeda S, et al. Pharmacology of a non-selective ETA/ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol 1995;114:949-54.
41. 41. Lee JY, Warner RB, Adler AL, Opgenorth TJ. Endothelin ETA receptor antagonist reduces myocardial infarction induced by coronary artery occlusion and reperfusion in the rat. Pharmacology 1994;49:319-24.
42. 42. McMurdo L, Thiemermann C, Vane JR. The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischemia and reperfusion. Br J Pharmacol 1994;112:75-80.
43. 43. Shubeita HE, McDonough PM, Harris AN, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. J Biol Chem 1990;265:20555-62.
44. 44. Ito H, Hiroe M, Hirata Y, et al. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994; 89:2198-203.